Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Nautilus Biotechnology (NASDAQ:NAUT) announced its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03, FiscalAI reports.

Here are the key takeaways from Nautilus Biotechnology’s conference call:

• Nautilus launched its Iterative Mapping Early Access Program in January (starting with the tau proteoform assay), with initial customer feedback described as encouraging but not expected to generate material revenue in 2026.
• The company publicly unveiled the Voyager instrument at US HUPO and reiterated a commercialization timeline of beta deployments, opening pre-orders in late 2026 and customer installations beginning in early 2027, which management expects will drive the recurring consumables revenue ramp.
• Technical progress and external validation advanced in Q4 — the broad-scale assay configuration change produced encouraging initial data, collaborators (Buck Institute, Allen Institute) reported novel tau proteoform biology, and an MJFF-funded $1.2M award to Nautilus will develop an alpha‑synuclein proteoform assay, signaling expansion beyond tau toward additional disease targets.
• Financially, Nautilus ended Q4 with $156.1M in cash and investments, reduced 2025 cash burn to $50.2M, expects 2026 cash burn of $65M–$70M with operating expense growth of ~15%–20%, and projects a cash runway extending through 2027.

Nautilus Biotechnology Stock Down 16.3%

Shares of NASDAQ NAUT traded down $0.47 during midday trading on Thursday, hitting $2.42. The stock had a trading volume of 309,381 shares, compared to its average volume of 222,722. The stock has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $1.56. The company has a market capitalization of $305.67 million, a PE ratio of -4.84 and a beta of 1.49. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $3.08.

Analyst Upgrades and Downgrades

NAUT has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell” and an average target price of $2.50.

Institutional Investors Weigh In On Nautilus Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in NAUT. Hudson Bay Capital Management LP acquired a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at about $37,000. Qube Research & Technologies Ltd acquired a new stake in Nautilus Biotechnology in the 2nd quarter valued at about $45,000. Virtu Financial LLC lifted its stake in Nautilus Biotechnology by 19.6% in the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after purchasing an additional 3,849 shares in the last quarter. XTX Topco Ltd lifted its stake in Nautilus Biotechnology by 86.2% in the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after purchasing an additional 30,641 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Nautilus Biotechnology by 468.3% during the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after purchasing an additional 50,871 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.